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Background: Diabetic nephropathy (DN) is one of the complex complications of Diabetes Mellitus (DM). The present
study has been designed to examine protective role of hydrogen Sulphide (H2S) donor against streptozotocin (STZ)
-induced behavioral, oxidative abnormalities and its DN like symptoms in rats.
Methods: For the induction of DN single intraperitoneal administration of STZ (45 mg/kg) was given till third week.
Behavioral parameters were measured on 1st, 7th, 21st and 42nd days and biochemical parameters were performed on
42nd day. All the drug treatments [NaHS (10 & 30 μmol/kg i.p), DL-propargylglycine (10 mg/kg i.p), standard
drug- Losartan (5 mg/kg p.o)] were given for 3 weeks staring from 21st day after the STZ injection.
Results: Three weeks treatment with sodium hydrosulphide (NaHS) (10 and 30 μmol/kg i.p,) significantly attenuated
the behavioral and biochemical abnormalities in STZ-treated animals. DL-propargylglycine (10 mg/kg i.p) pretreatment
with sub-effective dose of NaHS (30 μmol/kg i.p) significantly reversed the protective effect of NaHS. However,
combination of both NaHS (30 μmol/kg i.p) and standard drug losartan (5 mg/kg p.o) potentiated their effects as
compared to their effect alone.
Conclusion: The results of the present study suggest that H2S treatment showed significant improvement in
behavioral and biochemical abnormalities induced by STZ administration. Thus H2S represents a target of
treatment to prevent the progression of complications by DN.
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Diabetic nephropathy (DN) is the most common and ser-
ious complication of DM, which affects a large population
worldwide [1, 2]. However, the pathogenesis involved in
DN is still not clear [1–3]. DN is defined as partial loss of
function of kidney associated with nephrotic syndrome is
characterized by a glomerulosclerosis, glomerular and
renal-cell hypertrophy, podocyte loss, reduction in GFR,
elevation of MABP and fluid retention [4].
The single dose administration of STZ (45 mg/kg i.p.)
in rats has been shown to produce DN after 3–6 weeks.
Generally, three days (or) one week after STZ, animal
should be screened and those with fasting blood glucose
above 240 mg/dl are generally included in the studies of* Correspondence: punnubansal79@gmail.com
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creativecommons.org/publicdomain/zero/1.0/DN [5]. Now days, various drug strategies are being used
to understand the pathogenesis of DN and to design
suitable drug strategies.
Hydrogen sulfide (H2S) is a third gaseous bioactive
substance produced in different mammalian cells, both
exogenous and endogenous H2S have been reported to
cause vascular smooth muscle relaxation and decrease
in blood pressure [6], thus a physiological vasodilator
[7]. H2S significantly participates in the control of renal
functions and renal protection [8], including glomerular
and tubular functions, hypertension, atherosclerosis and
cardiac/renal ischemia–reperfusion injuries [9]. Also it
has been reported that H2S play important roles in cell
proliferation and apoptosis [10], neurotransmission, in-
flammatory processes [11–13], cirrhosis, sepsis, neurode-
generative disease, erectile dysfunction, and asthma [14].le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Showing experimental grouping and doses used
Group Treatment
1 Normal control
2 Disease control (STZ treated 45 mg/kg, i.p.)
3 STZ+ NaHS (10 μmol/kg i.p)
4 STZ+ NaHS (30 μmol/kg i.p)
5 STZ+ DL-Propergylglycine (10 mg/kg i.p) + NaHS
(30 μmol/kg i.p)
6 STZ+ Losartan (5 mg/kg p.o)
7 STZ+ Losartan (5 mg/kg p.o) + NaHS (10 μmol/kg i.p)
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and AT-I receptor antagonists are associated in compen-
satory decrease in release of renin. This may comprom-
ise the long term beneficial effects of these drugs.
However, ACE inhibitors may often associate with dry
cough, angioedema as side effect. In this regard H2S
donor is being suggested as better alternatives to ACE
inhibitors. H2S is shown to decrease the synthesis and
release of renin may produce additional beneficial ef-
fects. However, to our knowledge there is no previous
work has been carried out to explore the protective ef-
fect of NaHS against STZ-induced DN in rats.
Therefore, present study has been designed to eluci-
date the effect of NaHS and its possible renin mechan-




Male Wistar rats (250–300 g) bred in the Central Animal
House facility of I.S.F. College of Pharmacy, Moga, and
Punjab, India were used in the present study. Animals
were acclimatized to laboratory conditions prior to experi-
ments. They were housed in-group of three, under stand-
ard laboratory conditions of temperature (22 ± 1 °C),
relative humidity (60 %) and light/dark cycle. Rats were
fed on standard chow diet and water ad libitum. The ex-
perimental protocol was approved by the Institutional
Animal Ethics Committee (IAEC) of ISF College of
Pharmacy, Moga, Punjab, approval no. 162 dated 08
march 2014 and was carried out in accordance with the
guidelines of the Indian National Science Academy
(INSA) for the use and care of experimental animals.
Drugs and chemicals
Sodium Hydrosulphide and DL-propargylglycine were
purchased from Sigma Aldrich Ltd, (St. Louis, USA).
Losartan received as a gift sample from Kwality Pharma-
ceuticals Pvt. Ltd. (Amritsar). All other chemicals and
reagents used in present study were of analytical grade
and freshly prepared.
Treatment schedule
Total forty-two rats of either sex were used in study.
The animals were randomly divided into seven experi-
mental groups consisting of 6 animals in each (n =6) as
given in Table 1.
All the drugs in the present study were given for three
weeks staring from 21st day after the STZ induced DN.
The body weight, blood glucose level and blood pressure
were measured on 1st, 7th, 21st, 42nd days after STZ
administration. Terminally on 6th week animals were
sacrificed and kidneys were isolated to assess kidneys
weight and markers of oxidative stress such as reducedglutathione, lipid peroxidation, and nitrite levels. The
serum urea and creatinine levels were also measured by
using kits on 42nd day. The Histopathological studies
were carried out for different groups to estimate the
pathological changes of kidney. The experimental pro-
cedure is summarized in Fig. 1.Induction of experimental diabetic nephropathy
Diabetes mellitus was induced by single injection of STZ
(50 mg/kg, i.p.) (Vaishya et al., 2008), dissolved in freshly
prepared ice-cold citrate buffer (pH 4.5). After 1 week of
STZ administration animals having random serum glu-
cose more than 240 mg/dl were considered as diabetic.
The nephropathy developed after 3 weeks of STZ
administration.Assessment of STZ-induced diabetes
Estimation of serum glucose
At the end of the experimental protocol, the blood sam-
ples were collected from retro-orbital sinus and the
serum was separated. The glucose concentration was es-
timated by glucose oxidase-peroxidase (GOD-POD)
method using commercially available kits (Coral Clinical
System, Goa, India) [15].Estimation of body weight
Body weight was estimated in grams on day 1st, 7th,
21st, 42nd.Assessment of DN
Estimation of serum creatinine (SC)
The serum creatinine concentration was estimated on
42nd day by alkaline picrate method using commercially
available kit (Coral system, Goa, India) [16].Estimation of blood urea nitrogen (BUN)
The BUN was estimated at day 42th by Berthelot method
using the commercially available kit (Coral clinical system,
Goa, India [17].
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Both left and right kidneys were isolated at the end of
study on 42th day, renal fascia was removed and kidneys
were weighed individually. Total kidney weight/body
weight (%) was calculated according to following for-
mula [18, 19].
Calculation ¼ Left kidney weight gm:ð Þ þ Right kidney weight gm:ð Þ
Body weight gm:ð Þ
 100
Assessment of renal oxidative stress
The development of oxidative stress in the kidney
assessed by estimating renal thiobarbituric acid reactive
substance (TBARS), reduced form of glutathione (GSH)
and nitrite.
Tissue preparation
Animals were sacrificed on day 15 by decapitation and
the kidneys were removed and rinsed with ice-cold iso-
tonic saline. Liver separated out and weighed. Kidney
samples were then homogenized with ice-cold 0.1 mol/L
phosphate buffer (pH 7.4) 10 times (w/v). The homogen-
ate was centrifuged at 10,000 g for 15 min and aliquots
of supernatant were separated and used for biochemical
estimation.
Measurement of lipid peroxidation
The quantitative measurement of lipid peroxidation in
kidney was performed according to the method of Will’s,
1965. The amount of malondialdehyde (MDA), a meas-
ure of lipid peroxidation was assayed in the form of thio-
barbituric acid reacting substances (TBARS). TBARS
were quantified using an extinction coefficient of 1.56 ×
105 M−1 cm−1 and expressed as nmol of MDA per mg
protein [20].
Estimation of reduced glutathione
Reduced glutathione was estimated according to the
method described by Ellman, 1959. Reduced Glutathi-
one levels were measured at 412 nm using a Perkin
Elmer Lambda 20 spectrophotometer were calculated
using molar extinction co-efficient of the chromophore
(1.36 × 104 (mol/L) −1 cm−1) [21].
Estimation of nitrite
The accumulation of nitrite in the supernatant, an indi-
cator of the production of nitric oxide (NO), was deter-
mined with a colorimetric assay with Greiss reagent
[0.1 % N- (1-naphthyl) ethylenediame dihydrochloride,
1 % sulfanilamide and 2.5 % phosphoric acid] as de-
scribed by Green [22].Estimation of protein
Protein estimation was done by using protein estimation
kit (Coral kit).Measurement of mean arterial blood pressure (MABP)
The mean arterial blood pressure was recorded in rats
by tail-cuff apparatus (NIBPMP100, Biopac) containing
sensitive photoelectric sensors. To create sufficiently
large pulse volume oscillations, rats were exposed to
heat for about 12 min at 38 ° C prior to recording the
pressure. The heating increased the mean arterial pres-
sure by an average of 4 ± 2 mmHg, as indicated by direct
measurement of pressure. Three different sizes of cuffs
were tested. The MAP determined at maximum pulse
volume oscillations coincides fairly well with the true
mean arterial pressure [23].Histological studies
The early changes in glomeruli were assessed histologi-
cally as previously described [24]. The kidney was ex-
cised and immediately immersed in 10 % formalin. The
kidney was dehydrated in graded concentrations of alco-
hol, immersed in xylene and then embedded in paraffin.
From the paraffin blocks, sections of 3 μm in thickness
were made and stained with Hematoxylin and Eosin (H
& E) to assess the pathological changes occurs in glom-
eruli using light microscopy (10×).Statistical analysis
Values are expressed as mean ± SEM. The data for be-
havioral analysis were statistically analysed using two-
way ANOVA followed by Bonferroni post hoc test were
employed. The data for biochemical parameters were
analysed using two-way ANOVA test. A value of p < 0.05
was considered to be statistically significant.Results
Assessment of diabetes mellitus
Effect of NaHS on blood glucose level in STZ treated rats
The blood glucose levels were increased markedly in
STZ treated rats on 7th, 21st, 42nd day as compared to
control group. Treatment with NaHS (10 & 30 μmol/
kg i.p., 21 days) significantly decreased blood glucose
level in STZ treated rats as compared to vehicle treated
group. The losartan (5 mg/kg) alone had no effect on
blood glucose levels. Further, pretreatment with DL-p
(H2S inhibitor) was given along with NaHS (30 μmol/
kg), it significantly reversed the protective effect of
NaHS (30 μmol/kg) as compared with its effect alone.
The combination of losartan (5 mg/kg) and NaHS
(10 μmol/kg) also not produced synergistic effect on
blood glucose levels in STZ treated rats Fig. 1.
Fig. 1 Effect of NaHS on blood glucose level in STZ treated rats. aP < 0.05 versus vehicle treated, bP < 0.05 versus [STZ (45)] treated group, cP < 0.05
versus [STZ (45) + NaHS (10)] treated group, dP < 0.05 versus [STZ (45) + NaHS (30)] treated group. STZ = Streptozotocin, NaHS = Sodium
hydrosulphide, LOS = Losartan, DL-p = DL-propargylglycine
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rats
STZ treated rats shows significant decrease (~110 g) in
body weight on day 7th, 21st, 42nd as compared to control
group (~290 g). Treatment with NaHS (10 & 30 μmol/
kg i.p., 21 days) and losartan (5 mg/kg) significantly in-
creased body weight (~168 g, ~190 g respectively) in STZ
treated rats as compared to vehicle treated group. Further,
pretreatment with DL-p (H2S inhibitor) was given along
with NaHS (30 μmol/kg), it significantly reversed (~148 g)
the protective effect of NaHS (30 μmol/kg) as compared
with its effect alone. The combination of NaHS (10 μmol/
kg) and losartan (5 mg/kg) produced synergistic effect
(~215 g) as compared to their effects alone (~168 g, 165 g
respectively) in STZ treated rats.
Assessment of DN
Effect of NaHS and losartan on serum creatinine (SC) levels
in STZ treated rats
The SC levels were noted to be increased (1.8 mg/dl)
markedly in STZ treated rats on day 42nd as compared
to control group (0.8 mg/dl). Treatment with NaHS (10
& 30 μmol/kg i.p., 21 days) and losartan (5 mg/kg) sig-
nificantly decrease SC levels (1.63 mg/dl, 1.45 mg/dl,
1.50 mg/dl respectively) in STZ treated rats as compared
to vehicle treated group. Further, pretreatment with DL-
p (H2S inhibitor) was given along with NaHS (30 μmol/kg), it significantly reversed (1.68 mg/dl) the protective
effect of NaHS (30 μmol/kg) as compared with its effect
alone. The combination of NaHS (10 μmol/kg) and
losartan (5 mg/kg) shows synergistic effect (1.18 mg/dl)
in SC levels as compared to their effects alone (1.63 mg/
dl, 1.57 mg/dl) in STZ treated rats.
Effect of NaHS and losartan on blood urea nitrogen levels
(BUN) in STZ treated rats
STZ treated rats shows significant increase (75 mg/dl) in
blood urea nitrogen levels on day 42nd as compared to
control group (25 mg/dl). Treatment with NaHS (10 &
30 μmol/kg i.p., 21 days) and losartan (5 mg/kg) signifi-
cantly decreases BUN levels (65, 52, 66 mg/dl respect-
ively) in STZ treated rats as compared to vehicle treated
group. Further pretreatment with DL-p (H2S inhibitor)
was given along with NaHS (30 μmol/kg), it significantly
reversed (68 mg/dl) the protective effect of NaHS
(30 μmol/kg) as compared with its effect alone. The com-
bination of NaHS (10 μmol/kg) and losartan (5 mg/kg)
shows synergistic effect (37 mg/dl) in BUN levels as com-
pared to their effects alone in STZ treated rats.
Effect of NaHS and losartan on kidney weight/body weight
(KW/BW) ratio in STZ treated rats
STZ treated rats shows significant decrease in KW/BW
ratio (1.9 %) on day 42nd as compared to control group
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21 days) and losartan (5 mg/kg) significantly increase
KW/BW ratio (2.43, 2.94, 3.5 % respectively) in STZ
treated rats as compared to vehicle treated group. Fur-
ther, pretreatment with DL-p (H2S inhibitor) was given
along with NaHS (30 μmol/kg), it significantly reversed
(2.2 %) the protective effect of NaHS (30 μmol/kg) as
compared with its effect alone. Whereas, the combin-
ation of NaHS (10 μmol/kg) and losartan (5 mg/kg) pro-
duced synergistic effect (3.4 %) in KW/BW ratio as
compared to their effects alone in STZ treated rats.
Assessment of oxidative stress
Effect of NaHS and losartan on lipid peroxidation (LPO)
levels in STZ treated rat
STZ treated rats shows significant increase in LPO levels
on day 42nd as compared to control group. Treatment with
NaHS (10 & 30 μmol/kg i.p., 21 days) and losartan (5 mg/
kg) significantly decrease in LPO levels in STZ treated rats
as compared to vehicle treated group. Further, pretreatment
with DL-p (H2S inhibitor) was given along with NaHS
(30 μmol/kg), it significantly reversed the protective effect
of NaHS (30 μmol/kg) as compared with its effect alone.
Whereas, the combination of NaHS (10 μmol/kg) and
losartan (5 mg/kg) produced synergistic effect in LPO as
compared to their effects alone in STZ treated rats Fig. 2.
Effect of NaHS and losartan on reduced glutathione levels
STZ treated rats shows significant decrease in GSH
levels on day 42nd as compared to control group. Treat-
ment with NaHS (10 & 30 μmol/kg i.p., 21 days) andFig. 2 Effect of NaHS and losartan on Lipid Peroxidation in STZ treated rats
group, cP < 0.05 versus [STZ (45) + NaHS (10)] treated group, dP < 0.05 versus [S
treated group. STZ = Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Lolosartan (5 mg/kg) significantly increase in GSH levels in
STZ treated rats as compared to vehicle treated group.
Further, pretreatment with DL-p (H2S inhibitor) was given
along with NaHS (30 μmol/kg), it significantly reversed
the protective effect of NaHS (30 μmol/kg) as compared
with its effect alone. Whereas, the combination of NaHS
(10 μmol/kg) and losartan (5 mg/kg) produced synergistic
effect in LPO as compared to their effects alone in STZ
treated rats Fig. 3.
Effect of NaHS and losartan on nitrite levels in STZ treated
rats
STZ treated rats shows significant increase in nitrite
levels on day 42nd as compared to control group. Treat-
ment with NaHS (10 & 30 μmol/kg i.p., 21 days) signifi-
cantly decrease in nitrite levels in STZ treated rats as
compared to vehicle treated group. Further, pretreat-
ment with DL-p (H2S inhibitor) was given along with
NaHS (30 μmol/kg), it significantly reversed the protect-
ive effect of NaHS (30 μmol/kg) as compared with its ef-
fect alone. The losartan (standard drug) also shows
significant decrease in nitrite levels in STZ treated rats.
Whereas, the combination of NaHS (10 μmol/kg) and
losartan (5 mg/kg) produced synergistic effect in nitrite
as compared to their effects alone in STZ treated rats
Fig. 4.
Effect of NaHS and losartan on mean arterial blood
pressure (MABP)
STZ treated rats shows significant increase in MABP
levels on day 7th, 21st, 42nd as compared to control. aP < 0.05 versus vehicle treated, bP < 0.05 versus [STZ (45)] treated
TZ (45) + NaHS (30)] treated group, eP < 0.05 versus [STZ (45) + LOS (5)]
sartan, DL-p = DL-propargylglycine
Fig. 3 Effect of NaHS and losartan on Reduced Glutathione in STZ treated rats. aP < 0.05 versus vehicle treated, bP < 0.05 versus [STZ (45)] treated
group, cP < 0.05 versus [STZ (45) + NaHS (10)] treated group, dP < 0.05 versus [STZ (45) + NaHS (30)] treated group, eP < 0.05 versus [STZ (45) + LOS (5)]
treated group. STZ = Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p = DL-propargylglycine
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21 days) and losartan (5 mg/kg) significantly decrease in
MABP in STZ treated rats as compared to vehicle
treated group. Further, pretreatment with DL-p (H2S
inhibitor) was given along with NaHS (30 μmol/kg), it
significantly reversed the protective effect of NaHS
(30 μmol/kg) as compared with its effect alone. Whereas,
the combination of NaHS (10 μmol) and losartan (5 mg)Fig. 4 Effect of NaHS and losartan on Nitrite in STZ treated rats. aP < 0.05 v
versus [STZ (45) + NaHS (10)] treated group, dP < 0.05 versus [STZ (45) + NaHS (
STZ = Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Losartan, DL-pproduced synergistic effect in MABP levels as compared
to their effects alone in STZ treated rats Fig. 5.
Effect of NaHS and losartan on on renal histological study
The histopathological study shows that STZ administra-
tion results necrosis in glomerulus. NaHS and losartan
alone produced significant effects. Further treatment with
combinations of NaHS (10) + losartan (5) significantlyersus vehicle treated, bP < 0.05 versus [STZ (45)] treated group, cP < 0.05
30)] treated group, eP < 0.05 versus [STZ (45) + LOS (5)] treated group.
= DL-propargylglycine
Fig. 5 Effect of NaHS and losartan on MABP in STZ treated rats. aP < 0.05 versus vehicle treated, bP < 0.05 versus [STZ (45)] treated group, cP < 0.05
versus [STZ (45) + NaHS (10)] treated group, dP < 0.05 versus [STZ (45) + NaHS (30)] treated group, eP < 0.05 versus [STZ (45) + LOS (5)] treated group.
STZ = Streptozotocin, NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p = DL-propargylglycine
Kaur et al. Journal of Diabetes & Metabolic Disorders  (2015) 14:63 Page 7 of 10recovered histopathological changes. Whereas pretreat-
ment with inhibitor reverse the beneficial effects produced
by NaHS (30) Fig. 6.
Discussion
Diabetic Nephropathy was produced with single dose
administration of STZ (45 mg/kg i.p.) in rats. STZ-
induced DM rodents show secondary complications
after 3–6 weeks, as assessed in terms of SC, BUN, pro-
teinuria, CC, which is often associated with extracellular
matrix deposition, dyslipidemia and development of glo-
merulosclerosis and tubulointerstitial fibrosis [25]. Gen-
erally, 3 days (or) 1 week after STZ, animal should be
screened and those with fasting blood glucose above
240 mg/dL are generally included in the studies of DN
[26]. STZ damages the DNA of the pancreatic-β cells
and triggers multiple pathways, including activation of
protein kinase-C, poly (ADP-ribose) polymerase and
NAD(P)H oxidase, with consequent generation of ROS
and advanced glycation end products resulting in renal
damage and nephropathy [25–27]. The experimental evi-
dence suggests that STZ-induced diabetes downregulates
the expression and activity of eNOS and decreases the
bioavailability of NO, which aggravates nephropathy [5].
STZ treated rats shows significant increase in blood glu-
cose levels by increase the formation ROS by breaking the
single strand of DNA which leads to the activation of
PARP and result in apoptotic and necrotic death of Islets
of Langerhans [28, 29]. Nowadays, accumulating evidences
show that abnormal insulin regulation secretion has been
proved to be a significant effect on the weight loss of DNpatients. But the treatment with NaHS at low and high
dose significantly reduced the levels of blood glucose
levels by protecting the β-cells form the STZ induced
damage to β-cells and it also promote the secretion of in-
sulin [30]. Whereas losartan did not produce any signifi-
cant effect on blood glucose levels.
One of the most sensitive and dramatic indicators of
kidney injury is to increase the creatinine and urea level
in serum and in hepatocyte injury is the release of intracel-
lular enzymes, such as transaminases and serum alkaline
phosphatase in the circulation after STZ administration
[31, 32]. In addition, the soluble enzymes ALT/ASTare re-
leased when injury involves organelles such as mitochon-
dria [33]. Elevation of these levels causes severe damage to
nephron, which indicates the abnormal kidney function-
ing, which was considered as significant markers of renal
dysfunction [34]. After the 3-week treatment with NaHS
and losartan alone or in combination produce significantly
decrease in serum creatinine and BUN levels in STZ-
diabetic rats [35].
The incidence and severity of lesions produced by STZ
in pancreas, liver, kidney and GIT, progressively in-
creased with time from one to six weeks post treatment,
which results increase in kidney weight/body weight ra-
tio as compared with the control group [36]. But treat-
ment with NaHS and losartan alone or in combination
showed a significant improvement in reduced body
weight and increased kidney weight/body weight ratio.
A growing body of evidence showed that oxidative
stress (OS) played a crucial role in the development and
progression of DN [37]. ROS, the result of excessive
Fig. 6 Hemotoxylin-Eosin stained longitudinal section of kidneys (10×). A- Normal control, B- STZ treated group (45), C- NaHS (30), D- DL-p (10) +
NaHS (30), E-LOS, F- NaHS (10) + Losartan (5)
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induce mitochondrial dysfunction, decline adenosine tri-
phosphate, and then lead to DN [39]. Advanced glyca-
tion end products (AGEs), playing a central role in DN,
are accumulated in glomerular basement membrane,
mesangial cells, and endothelial cells [40]. The inter-
action between AGEs and their specific receptors could
trigger OS damage and then lead to signaling cascade
events [37]. Transforming growth factor beta family
(TGF-β) was reported to have great relationships with OS
via the regulation of protein levels of antioxidant enzymes
such as superoxide dismutase (SOD), glutathione peroxid-
ase (GSH-PX), catalase (CAT), and others [41]. The
present study show that there is significant (p < 0.05) de-
crease in the LPO, nitrite and significant (p < 0.05) in-
crease in the level of GSH in STZ treated group so which
revealed the antioxidant action of NaHS and losartan.
STZ administration (45 mg/kg, i.p, once) resulted sig-
nificant increase in MABP. From the previous studies it
has been observed that the development of renovascular
hypertension depends on the release of renin from
the juxtaglomerular (JG) cells, a process regulated by
intracellular cAMP. Hydrogen sulfide (H2S) downre-
gulates cAMP production in some cell types by inhi-
biting adenylyl cyclase, suggesting the possibility that
it may modulate renin release. Here, we investigated
the effect of H2S on plasma renin activity and BP in
rat models of STZ induced DN hypertension.
The H2S is beneficial at physiological concentrations
but detrimental at supra physiological concentrations.H2S significantly participates in the control of renal
functions, including glomerular and tubular functions.
We postulated that hyperglycemia would also decrease
CSE expression in the kidney, which may cause renal
microcirculation injury and renal ischemia [42, 43].
Endothelial dysfunction attributable to eNOS reduction
and insulin deficiency might induce decreased peritubu-
lar capillaries blood flow, resulting in tubulointerstitial
ischemia and injury [44]. Anti-apoptotic effects of H2S
have also been reported in other types of cells [45]. H2S
also promotes angiogenesis through VEGF signaling
pathways such as the PI3K-Akt pathway [45]. As the bio-
logical features of H2S resemble those of NO, modula-
tion of H2S production might be involved in diabetic
tubulointerstitial ischemia. Further, high glucose further
induces the CSE expression in the β-cells in pancreas, in
contrast to the renal proximal tubules [46]. These sug-
gest that H2S may protect β-cells from glucotoxicity,
eventually leading to the promotion of insulin secretion
[47]. It has been demonstrated that NaHS administration
increased blood flow by PTC dilation. Indeed, CSE re-
duction results in decreased H2S formation [47].
Cytoprotection by H2S is associated with the inhibition
of reactive oxygen species (ROS) production via inhib-
ition of NADH oxidase [48], the induction of anti-
oxidative molecules such as thioredoxin [49], and an in-
crease in glutathione (GSH) production [50]. Therefore,
β-cell protection is the focus of new strategies for the
treatment of diabetes [30]. At physiological concentra-
tions of H2S produce anti-inflammatory effects [14].
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of iNOS expression, NO production and tumor necrosis
factor-a (TNF-a) expression in cultured microglia [12].
In conclusion, these results demonstrate that H2S may
inhibit renin activity by decreasing the synthesis and re-
lease of renin, suggesting its potential therapeutic value
for renovascular hypertension.
Conclusions
In conclusion, we hypothesized NaHS showed their pro-
tective effect by increasing the production of H2S by the
activation of CSE enzyme that ultimately leads to min-
imizing the secondary complication of the DM in STZ
induced DN. Further hydrogen sulphide donor produce
synergistic effect along with standard Losartan. There-
fore we conclude that NaHS has shown protective effect
in DN rats but combined treatment with standard pro-
duce more significant results.
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